KR20140056990A - Composition for preventing or treating alopecia, or promoting hair growth comprising baicalin - Google Patents

Abstract

The present invention relates to a composition for preventing or treating hair loss or promoting hair growth comprising baicalin as an active ingredient. The baicalin according to the present invention induces the Wnt signaling through the ß-catenin pathway in the dermal papilla cells, increases the expression of alkaline dephosphorylase, increases the expression of hair growth factor, induces hair growth, The hair growth promoting function and hair follicle formation inducing ability are excellent, and thus it can be effectively used for preventing or treating hair loss, or promoting hair growth, and can be usefully used as an additive to a culture solution when developing a hair follicle cell therapeutic agent.

Description

[0001] The present invention relates to a composition for prevention or treatment of hair loss comprising baicalin as an active ingredient, or a composition for promoting hair growth,

The present invention relates to a composition for preventing or treating hair loss or promoting hair growth comprising baicalin as an active ingredient.

The history of baldness is very long and the history of prescription for hair loss treatment is also known to have been written in Papyrus of Egypt more than 5,000 years ago. Hipocrates, famous Greek about 400 BC, Unfortunately, many of the modern people as well as the ancients have shown great interest in baldness and hair loss treatment and hair growth techniques, but they have not reached the technology. Respectively.

In modern society, the living body is slowly damaged due to a lot of stress, and hair loss caused by it is becoming a big social issue. Hair loss is caused by a lack of growth factors that slow hair growth and promote hair follicle cell growth.

It is also known that hair loss accelerates by early death of hair and hair follicle cells. Therefore, the development of factors to overcome this will be a goal to overcome hair loss. Hair loss is caused by various causes and has a high incidence worldwide. In addition, hair loss reduces the quality of life by mental stress and affects interpersonal relationships and social life. Such hair loss is related to various diseases, and as the social climate that emphasizes the appearance is progressing considerably, nowadays it has become more interested in the cause and treatment as a disease, and recently it is accepted as an issue. In addition to genetic factors, hair loss is caused by external factors such as stress or environmental pollution, regardless of gender or age, and it is estimated that the number of hair loss in Korea increased from about 5 million in 2006 to 9 million this year. In this regard, the market for hair growth and hair loss prevention is rapidly expanding and the domestic market has grown from about 800 billion won in 2005 to about 2 trillion won this year. The market for hair loss treatments was about 30 billion won in 2007, and it reached about 50 billion won in 2010.

Currently, many balms and hair loss preventive drugs are on the market globally, but there are still few drugs or technologies that can satisfy the therapeutic effect. The US Food and Drug Administration (FDA) has approved the FDA as the only drug approved as a hair growth promoter after minoxidil was originally marketed as a side effect, a side effect discovered as a hypertension remedy and the first to be approved by the US federal government Baldness and alopecia. Another drug currently in use is Propecia, which is based on the hormone hypothesis of hair loss. The male hormone is converted to the metabolite dihydrotestosterone (DHT) by the action of 5-alpha reductase The material is known to atrophy and destroy hair follicles. The effect of blocking the 5-alpha reductase inhibits the production of DHT and inhibits the progression of male-type hair loss to the utmost. The effect of the drug is to prevent hair loss, not hair growth. In addition, substances known to be effective in preventing hair growth and hair loss have been reported. For example, the compounds include cyclosporin derivatives (Korean Patent No. 10-0439467, Korean Patent No. 10-0695611), N-heterocyclic carboxylic acids and carbamates (Korean Patent Laid-Open No. 10-2001-0052502) (Korean Patent Laid-Open Publication No. 10-1999-0023754), crysine 7-O-crotonate (Korean Patent Laid-Open No. 10-2001-0009474), and 1,2-disubstituted benzenecarboxamide derivatives 1999-0037394) have been reported. Among the natural substances having less side effects, there have been reported that the natural products such as ginseng extract (Korea Patent Publication No. 10-2005-0102346), apricot seed oil (Korea Patent Publication No. 10-2004-0092755) 10-2006-0008662), Baekjong extract (Korean Patent Laid-Open No. 10-2005-0102345), Indigo extract (Korean Patent Laid-open No. 10-2005-0077310), and Phellinus linteus extract (Korean Patent No. 10-0348155) . The effect of these substances is insignificant, so long - term treatment is required to expect the effect, and hair loss is again on progress at the time of discontinuation. Therefore, in many cases, side effects that may occur over a long period of time and that are used over a period of time can also increase patient pain.

On the other hand, mammalian hair follicles are composed of facial root, epididymal root, substrate, hair follicle derived from epidermal cells, hair follicle and mesenchymal tissue derived from epithelial cells. Hair growth is a complex interplay of epithelial cells and dermal cells of the hair follicle. Depending on their interaction, the hair grows in vigorous anagen, catagen, and telogen Cycle the cycle. Hair growth is a dermal papilla (DP) of the hair follicle, and it circulates in a growth or degradation state by releasing a hair growth factor or an inhibitory factor to the hair matrix cells surrounding it [Botchkarev VA, Kishimoto J. et al. Molecular control of epithelial-mesenchymal interactions during hair follicle cycling. J Investig Dermatol 2003; 8 : 46-55. Stenn KS, Paus R. Controls of hair follicle cycling. Physiol Rev 2001; 81 : 449-94,1, 2]. In addition, dermis cells such as dermal papilla cells and dermal sheath cells have the ability to interact with epithelial cells to form new hair [Jahoda CAB, Horne KA, Oliver RF. Induction of hair growth by implantation of cultured dermal papilla cells. Nature 1984; 311: 560-2. Yang CC, Cotsarelis G. Review of hair follicle dermal cells. J Dermatol Sci 2010 57: 2-11].

Recent studies have demonstrated that Wnt signaling through the ß-catenin pathway is necessary for maintaining the growth characteristics of dermal papilla cells and maintaining the ability to induce hair [Kishimoto J, Burgeson RE, Morgan BA. Wnt signaling maintains the hair-inducing activity of the dermal papilla. Genes Dev 2000; 14: 1181-5. Shimizu H, Morgan BA. Wnt signaling through the β-catenin pathway is sufficient to maintain, but not restore, anagen-phase characteristics of dermal papilla cells . J Invest Dermatol 2004; 122: 239-45. Enshell-Seijffers D, Lindon C, Kashiwagi M et al . beta-catenin activity in the dermal papilla regulates morphogenesis and regeneration of hair. Dev Cell 2010 18: 633-42.11-13]. Through this pathway, alkaline phosphatase activity is strongly expressed in the dermal papilla during the follicular growth period and is used as a useful marker to indicate size, shape and location of the dermal papilla (Iida M, Ihara S, Matsuzaki T. Hair cycle-dependent changes in alkaline phosphatase activity in the mesenchyme and epithelium in mouse vibrissal follicles. Dev Growth Differ 2007 49: 185-95. 14,15]. In addition, when dermal cells such as dermal papilla and cytoplasmic cells, which are activated by alkaline dephosphorylase, are planted in the ears and soles of mice, a new hair follicle is formed unlike cells that have lost the activity of alkaline dephosphorylase [McElwee KJ, Kissling S, Wenzel E meat al . Cultured peribulbar dermal sheath cells can induce hair follicle development and contribute to the dermal sheath and dermal papilla. J Invest Dermatol 2003; 121: 1267-75. Thus, the activity of the alkaline dephosphorylase is known to be a marker of dermal papilla cells and a marker of maintaining trichogenicity.

On the other hand, bicalin, one of the flavonoids, is known to have antioxidant, anti-cancer and anti-inflammatory effects as a component contained in gold [Jung SH, Kang KD, Ji D et al. The flavonoid baicalin counteracts ischemic and oxidative insults to retinal cells and lipid peroxidation to brain membranes. Neurochem Int 2008 53 : 325-337. Li-Weber M. New therapeutic aspects of flavones: the anticancer properties of scutellaria and its main active constituents wogonin, baicalein and baicalin. Cancer Treat Rev 2009 35 : 57-89]. It is also known that baicalin plays an important role in the ß-catenin / Wnt signaling pathway in osteoblasts.

As described above, various pharmacological effects of baicalin are known, but the effect of preventing or treating hair loss, or promoting hair growth has not been known at all, and there has been no research on it

The present inventors confirmed that activating the Wnt signaling system through the ß-catenin pathway in the baculovirus human dermal papilla cells, increasing the expression of alkaline dephosphorylase and increasing the expression of hair growth factor, And inducing hair follicle formation, thereby completing the present invention.

It is an object of the present invention to provide a pharmaceutical composition for preventing or treating hair loss comprising Baikalin as an active ingredient.

Another object of the present invention is to provide a cosmetic composition for preventing hair loss and promoting hair growth comprising baicalin as an active ingredient.

It is still another object of the present invention to provide a food composition for preventing hair loss and promoting hair growth comprising baicalin as an active ingredient.

In order to achieve the above object, there is provided a pharmaceutical composition for preventing or treating hair loss comprising Baikalin as an active ingredient.

Another object of the present invention is to provide a cosmetic composition for preventing hair loss and promoting hair growth comprising baicalin as an active ingredient.

Yet another object of the present invention is to provide a food composition for preventing hair loss and promoting hair growth, which comprises baicalin as an active ingredient.

The baicalin according to the present invention activates the Wnt signaling pathway through the ß-catenin pathway in the dermal papilla cells, increases the expression of alkaline dephosphorylase, increases the expression of hair growth factors, induces hair growth, The hair growth promoting function and the hair follicle formation inducing ability are excellent, and thus it can be usefully used for preventing or treating hair loss and promoting hair growth, and it can be usefully used as an additive to a culture solution when developing a hair follicle cell therapeutic agent.

1 is a graph showing the activity of ß-catenin after treatment of human dermal papilla cells with baicalin of the present invention.
Fig. 2 is a graph showing the activity of alkaline dephosphorylase after treatment of human dermal papilla cells with baicalin of the present invention. Fig.
3 is a graph showing the expression level of alkaline dephosphorylase after treatment of human dermal papilla cells with baicalin of the present invention.
FIG. 4 is a graph showing the expression level of IGF-1 (insulin like growth factor 1) after treatment of human dermal papilla cells with baicalin of the present invention.
FIG. 5 is a graph showing the expression level of VEGF (vascular endothelial growth factor) after treatment of human dermal papilla cells with baicalin of the present invention.
Fig. 6 is a graph showing the hair growth effect after treating the mouse with the baicalin of the present invention. Fig.
Fig. 7 is a graph showing the follicle-forming ability after treating the mouse with the baicalin of the present invention.

The present invention provides a composition for preventing or treating hair loss, or for promoting hair growth, comprising baicalin represented by the following formula (1) as an active ingredient.

[Chemical Formula 1]

The composition comprises a pharmaceutical composition, a cosmetic composition and a food composition.

Hereinafter, the present invention will be described in detail.

The baicalin according to the present invention activates the Wnt signaling pathway through the ß-catenin pathway in human dermal papilla cells, increases the expression of alkaline dephosphorylase, increases the expression of hair growth factors, promotes hair growth, Lt; / RTI > Accordingly, the baicalin according to the present invention can be used as medicines, cosmetics, and health functional foods useful for preventing or treating hair loss, or promoting hair growth.

The composition of the present invention may contain at least one known active ingredient having alopecia prevention or treatment or hair growth promoting effect together with baicalin.

The composition of the present invention may further comprise at least one pharmaceutically acceptable carrier in addition to the above-described effective ingredients for administration. The pharmaceutically acceptable carrier may be a mixture of saline, sterilized water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and one or more of these components. If necessary, an antioxidant, , And other conventional additives such as a bacteriostatic agent may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like. Further, it can be suitably formulated according to each disease or ingredient, using appropriate methods in the art or by the method disclosed in Remington's Pharmaceutical Science (recent edition), Mack Publishing Company, Easton PA.

The composition of the present invention may be administered orally or parenterally (for example, intravenously, subcutaneously, intraperitoneally or topically) depending on the intended method, and the dose may be appropriately determined depending on the patient's weight, age, , Diet, administration time, method of administration, excretion rate, and severity of the disease. The daily dose of the baicalin is about 0.1 to 1000 mg / kg, preferably about 10 to 100 mg / kg, and is preferably administered once a day to several times a day.

The composition of the present invention can be used alone or in combination with methods using surgery, hormone therapy, drug therapy and biological response modifiers for hair loss prevention or treatment, or hair growth stimulation.

In addition, the composition of the present invention can be used as an external preparation for preventing or treating hair loss, or promoting hair growth. When the baicalin of the present invention is used as a external preparation, it is further possible to use a fatty substance, an organic solvent, a solubilizer, a thickening agent and a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, For example, water, ionic or nonionic emulsifiers, fillers, sequestering agents and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or external preparations for skin And may contain adjuvants commonly used in the related art, such as any other ingredients used. The components may also be introduced in amounts conventionally used in the related art. The external preparation may be any one selected from the group consisting of cream, lotion, ointment, gel, mucilage, spray and wetting agent, but is not limited thereto.

When the external preparation is used as a cosmetic product, it can be prepared in the form of a general emulsified formulation and a solubilized formulation. Emulsifier-type cosmetics include nutritional lotion, cream, and essence, and cosmetics of the solubilized formulation have softening longevity. Suitable cosmetic formulations include, for example, solutions, gels, solid or kneaded anhydrous products, emulsions obtained by dispersing the oil phase in water, suspensions, microemulsions, microcapsules, microgranules or ionic (liposomes) In the form of a dispersing agent, in the form of a cream, a skin, a lotion, a powder, an ointment, a spray or a conical stick. It can also be prepared in the form of a foam or an aerosol composition further containing a compressed propellant. In addition, it can be used variously as a hair cosmetic having an effect of preventing hair loss and activating hair growth. Hair cosmetics include, for example, hair tonic, hair conditioner, hair essence, hair lotion, hair nutrition lotion, hair shampoo, hair rinse, hair treatment, hair cream, hair nutrition cream, hair moisturizing cream, Hair dyes, hair lacquers, hair dyes, hair dyes, hair dyes, hair dyes, hair dyes, hair dyes, hair dyes, hair dyes, hair fresheners, Cosmetics such as hair moisturizers, hair mousse, hair sprays, and the like.

In the cosmetic composition of the present invention, it is preferable that baicalin is contained in an amount of 0.01 to 10% by weight based on the total weight of the cosmetic composition.

The baicalin of the present invention may be added to a health functional food for the purpose of preventing or improving hair loss, or promoting hair growth. When the baicalin of the present invention is used as a food additive, the baicalin may be added as it is or may be used together with other food or food ingredients, and may be appropriately used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health or therapeutic treatment). Generally, in the production of food or beverage, it is added in an amount of not more than 15% by weight, preferably not more than 10% by weight based on the raw material of baicalin of the present invention. However, in the case of long-term intake for the purpose of health and hygiene or for the purpose of health control, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range.

There is no particular limitation on the kind of the food. Examples of the food to which the above substances can be added include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include health functional foods in a conventional sense.

The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. The above-mentioned natural carbohydrates are monosaccharides such as glucose and fructose, polysaccharides such as disaccharides such as maltose and sucrose, dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 0.20 g, preferably about 0.04 to 0.10 g per 100 of the composition of the present invention.

In addition to the above, the composition of the present invention may further contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acids and salts thereof, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, A carbonating agent used in a carbonated beverage, and the like. In addition, the composition of the present invention may contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. Although the ratio of such additives is not critical, it is generally selected in the range of 0.01 to 0.20 parts by weight per 100 parts by weight of the composition of the present invention.

Hereinafter, the present invention will be described in detail with reference to Examples, Experimental Examples and Production Examples.

However, the following Examples, Experimental Examples and Preparation Examples illustrate the present invention concretely, and the contents of the present invention are not limited by Examples, Experimental Examples and Production Examples.

[ Example  One] Baikal's  ß- catenin  Active measurement

One. All  Cell culture

Biopsy tissue (4 mm) was obtained during the hair transplantation procedure in male hair loss patients. The hair follicles were separated by slight modification of the previously reported method [Philpott MP, Sanders DA, Westgate GE, Kealey T J Invest Dermatol 1994; 102: 857-61; Magerl M, Kauser S, Paus R, Tobin DJ. Exp Dermatol 2002; 11: 381-5]. More specifically, the subcutaneous fat portion of the scalp including the lower portion of the hair follicle was separated from the epidermis and dermis, and the hair follicle was separated using a tweezers under a microscope. The dermal papilla cells were separated from the follicles of the amputated hair follicles and transferred to a type I collagen coated culture dish and cultured in DMEM supplemented with penicillin (100 U / ml), streptomycin (100 ug / ml) and 20% heat- Eagle's Medium) at 95% air, 5% CO ₂ and 37 ° C. After incubation for one week, when the dermal papilla cells were attached to the culture dish and the cells started to spread out, the medium was changed every three days. When cells were grown, the cells were collected using 0.25% trypsin / 10 mM EDTA and maintained in 10% DMEM at a ratio of 1: 3 to cultivate dermal papilla cells.

2. People's In dermal papilla cells Baikal's  ß- catenin  Active measurement

450 ng of Topflash (TCF Repoter plasmid) having DNA sequence binding to TCF transcription factor in response to ß-catenin was introduced into human dermal papilla cells using a microporator and 50 ng of pRLCMV vector was introduced as a control for quantitation . After 24 h of introduction of the reporter vector, the cells were treated with serum (0, 10, 20, 50, 100 [mu] M) for bacalin in serum-free medium. Twenty-four hours later, the firefly and renilla luciferase activities were measured using a dual luciferase assay kit to confirm the β-catenin activity of bicalyin. The results are shown in FIG. 1 (data are plotted as mean +/- standard deviation based on two independent experiments on two runs per condition).

As shown in FIG. 1, the activity of luciferase was significantly increased in the group treated with bicalyin, and the activity of luciferase was increased as the treatment concentration of bicalyin was increased. It can be seen that baicalin activates the signal pathway to ß-catenin.

[ Example  2] people In all flow cells Baikal's  Alkaline Dephosphorylation  Enzyme activity recovery confirmation

1. Alkalinity using optical microscope Dephosphorylation  Enzyme activity confirmation confirmation

Human dermal papilla cells cultured in Example 1 were grown on a chamber slide and treated with bicalyin (10, 50, 100 μM) for 48 hours, respectively, and fixed with 100% methanol for 10 minutes. Washed twice with PBS and 5 μl of NBT (nitroblue tetrazolium) and 3.75 μl of 5-bromo-4-chloro-3-indolyl phosphate (BCIP) were added to the slide for 20 min at room temperature. Thereafter, the cells were washed with water, covered with a cover glass, and examined by an optical microscope to confirm that bicalin enhances the activity of alkaline dephosphorylase. The results are shown in Fig.

As shown in FIG. 2, the activity of alkaline dephosphorylase was enhanced in the group treated with 10, 50 and 100 uM of bicalyin, as compared with the control group in which the alkaline dephosphorylase was remarkably reduced.

2. Real time RT - PCR Alkalinity using Dephosphorylation  Confirmation of enhancement of enzyme expression

Human dermal papilla cells were treated with 50 μM bicanalin for 24 hours, or untreated, and total RNA was isolated. More specifically, cDNA was synthesized from 3 total total RNA using Superscript II reverse transcriptase (Invitrogen) and oligo dT. Real-time PCR was performed by SYBR green method using the synthesized cDNA and primers for alkaline dephosphorylase. SYBR Green I is an interchelator that binds to double-stranded DNA and displays fluorescence. Interchelator was able to bind to double stranded DNA synthesized by PCR reaction and generate fluorescence, and the amount of amplification product could be measured by detecting this fluorescence intensity. The degree of expression of the alkaline dephosphorylase is shown in Figure 3 (data are run in duplicate for each condition and expressed as mean +/- standard deviation based on three independent experiments).

As shown in Fig. 3, it was confirmed that the expression of the alkaline dephosphorylase gene was increased after treating human dermal papilla cells with bicalin. From the above results, it was confirmed that by increasing the expression of the bacalin de-phosphorylase gene, it is possible to induce the formation of hair follicles.

[ Example  3] people In all flow cells Baikal's  Promoting the expression of growth factors

In the same manner as in Example 2-2, human dermal papilla cells were treated with 50 쨉 M of bacalin or non-treated with bacalin to stimulate hair growth, and insulin like growth factor 1 (IGF-1) and vascular endothelial growth Factor expression was confirmed using real-time PCR and the results are shown in FIG. 4 and FIG. 5 (data are run two per each condition and the average +/- standard Deviations).

As shown in Figs. 4 and 5, it was confirmed that the expression of IGF-1 and VEGF was increased after treatment of human dermal papilla cells with bicalin. From the above results, it was confirmed that bicalkine can increase hair growth.

[ Example  4] in the mouse Baikal's  Check the effect of hair growth

C57BL / 6, female, 7-week-old mice (Orient Bio, Gyeonggi-do) were purchased and stabilized for 3-4 days, anesthetized with Forane (China Pharmaceutical) and hair removed using an electric shaver. After 1-2 days, 80uM of bacalin was applied topically (150ul each) for 4 weeks and photographed. The results are shown in Fig.

As shown in FIG. 6, in the group treated with baicalin, hair growth was promoted as compared with the untreated control group.

[ Example  5] In the mouse Baikal's Follicular neoplasm  Confirm

Skin was removed from C57BL / 6 mice immediately after birth to remove subcutaneous fat and treated with dispase and collagenase at 4 ° C. After 16 ~ 18 hours of treatment with the enzyme, the dermis and epidermis were separated and placed in 0.25% trypsin / 10 mM EDTA, respectively, and allowed to stand at 37 ° C for 30 minutes. Dermal cells were isolated. Separated epidermal cells were cultured in EpiLife medium for 3 days at 95% air, 5% CO ₂ and 37 ° C. Dermal cells were cultured for 3 days in DMEM supplemented with 10% heat-inactivated serum depending on the presence or absence of baicalin. Three days later, the epidermal cells and dermal cells were detached using 0.25% trypsin / 10 mM EDTA, mixed with 1: 1 10 ⁶ each, and centrifuged at 1200 rpm for 5 minutes to submerge the cells. 100 쨉 l of PBS was added to the cell pellet and then injected into subcutaneous tissues of female 7-week-old nude mice using a 23G syringe. After 2 weeks of injection, hair follicle nephropathy was confirmed and the results are shown in FIG.

As shown in FIG. 7, an average of 35 control groups treated with bicalin and 188 hair follicles treated with bicalyin were formed, indicating that bicalin increases the hair follicle-forming ability of mouse dermal cells.

Formulation example  One  : Preparation of pharmaceutical preparations

1. Manufacturing of powder

Baikalin 200 ml

Lactose 100 ml

The above components were mixed and packed in airtight bags to prepare powders.

2. Preparation of tablets

Baikalin 200 ml

Corn starch 100 ml

Lactose 100 ml

Magnesium stearate 2 ml

After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.

3. Preparation of capsules

Baikalin 200ml

Corn starch 100ml

Lactose 100ml

Magnesium stearate 2ml

After mixing the above components, the capsules were filled in gelatin capsules according to the conventional preparation method of capsules.

4. Preparation of injections

Baikalin 200ml

       Mannitol 100ml

Na ₂ HPO ₄ 2H ₂ O 2 ml

Sterile sterilized water for injection

Injection was prepared by mixing the above components per ampoule (2) according to the usual injection preparation method.

Formulation example  2: Cosmetic manufacturing

1. Manufacture of hair tonic

Baikalin 1%

Resorcinol 0.1%

Menthol 0.05%

Panthenol 0.2%

Salicylic acid 0.1%

Tocopheryl acetate 0.1%

0.1% of pyridoxine hydrochloride

Castor oil 5.0%

Pigment amount

Tonic dose

Ethanol quantity

Purified water balance

All 100%

2. Manufacture of hair conditioner

Baikalin 0.5%

Cetanol 3.5%

Self-emulsifiable glycerin monostearate 1.5%

Propylene glycol 2.5%

Stearylmethylbenzylammonium chloride 7.0%

Methyl paraoxybenzoate 0.3%

Pigment amount

Fragrance quantity

Purified water balance

Total 100.0%

3. Manufacture of Hair Lotion

Bocalin 5.0%

Resorcinol 2.0%

Menthol 2.0%

Panthenol 0.5%

0.0 > 0.1% < / RTI &

Flavor, coloring 0.5%

Purified water balance

Total 100.0%

4. Manufacture of hair soap

0.1%

Titanium dioxide 0.2%

Polyethylene glycol 0.8%

Glycerin 0.5%

Ethylenediamine tetraacetic acid 0.05%

Sodium 1.0%

Pigment amount

Soap perfume

Soap base balance

Total 100%

Formulation example  3  : Manufacturing of food

Foods containing the baicalin of the present invention were prepared as follows.

1. Preparation of cooking seasoning

Healthy cooking sauce was prepared with 20 ~ 95 wt.% Of baicalin.

2. Preparation of tomato ketchup and sauce A toe ketch or sauce was prepared.

3. Manufacture of flour food

0.5 to 5.0% by weight of baicalin was added to wheat flour, and bread, cake, cookies, crackers and noodles were prepared using this mixture to prepare foods for improving hair loss.

4. Manufacture of soups and gravies

0.1 to 5.0% by weight of baicalin was added to soup and juice to prepare a meat product for improving hair loss, noodle soup and juice.

5. Manufacture of ground beef

10% by weight of bicalyin was added to the ground beef to prepare a ground beef for improving hair loss.

6. Manufacture of dairy products

5 to 10% by weight of baicalin was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.

Formulation example  4  : Manufacture of beverages

1. Manufacture of carbonated beverages

The syrup was prepared by mixing additives of 10-15% of baicalin, 5-10% of sugar, 0.05-0.3% of citric acid, 0.005-0.02% of caramel and 0.1-1% of vitamin C and 75-80% of purified water . The syrup was sterilized at 85 to 98 for 20 to 180 seconds, mixed with cooling water at a ratio of 1: 4, and 0.5 to 0.82% of carbon dioxide gas was injected to prepare a carbonated drink containing bicalin.

2. Manufacture of health drinks

(70%, 0.12%), vitamin C (0.02%), calcium pantothenate (0.02%), licorice extract (Solid content: 65%, 0.01%) were uniformly blended, instant sterilized, and packaged in small containers such as glass bottles and plastic bottles to produce health drinks.

3. Manufacture of vegetable juice

0.5 g of Baikalin was added to 1,000 tomato or carrot juice to prepare vegetable juice for improving hair loss.

4. Manufacture of fruit juice

0.1 g of Baikalin was added to 1,000 apples or grape juice to prepare fruit juice for improving hair loss.

Claims (9)

A pharmaceutical composition for preventing or treating hair loss comprising Baikalin represented by the following formula (1) as an active ingredient.
[Chemical Formula 1]

The pharmaceutical composition according to claim 1, wherein the baicalin increases expression of IGF-1 (insulin like growth factor I) and vascular endothelial growth factor (VEGF) in dermal papilla cells. The pharmaceutical composition for preventing or treating hair loss according to claim 1, wherein the baicalin increases β-catenin activity of the dermal papilla cells. The pharmaceutical composition for preventing or treating hair loss according to claim 1, wherein the baicalin increases the activity and expression of alkaline dephosphorylase in the dermal papilla cells. The pharmaceutical composition for preventing or treating hair loss according to claim 1, wherein the baicalin induces hair follicle formation. 1. A cosmetic composition for preventing hair loss and promoting hair growth comprising Baikalin represented by the following formula (1) as an active ingredient.
[Chemical Formula 1]

[7] The cosmetic composition for preventing hair loss and promoting hair growth according to claim 6, wherein the baicalin is contained in an amount of 0.01 to 10% by weight based on the total weight of the cosmetic composition. The cosmetic composition according to claim 6, wherein the cosmetic composition is at least one selected from the group consisting of hair tonic, hair conditioner, hair essence, hair lotion, hair nutrition lotion, hair shampoo, hair conditioner, hair treatment, hair cream, hair nutrition cream, Hair wax, hair aerosol, hair pack, hair nutrition pack, hair soap, hair cleansing foam, hair oil, hair drying agent, hair preservative, hair dye, hair wave agent, hair bleaching agent, hair gel, hair glaze, hair dresser, hair Wherein the composition is formulated into at least one selected from the group consisting of lacquers, hair moisturizers, hair mousses, and hair sprays. 1. A food composition for preventing hair loss and promoting hair growth comprising Baikalin represented by the following formula (1) as an active ingredient.
[Chemical Formula 1]

Images